Clinical Trial Update: Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of gemcitabine and topotecan in recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Hycamtin (Topotecan)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED